Cipla poised to maintain high growth, earnings may grow by ove...

"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.

GRUH Finance Ltd, Cipla Ltd, Ujjivan Financial Services Ltd and Grasim Industries Ltd are among the other gainers in the BSE's 'A' group today, 16 April 2018. Indiabulls Ventures Ltd soared 13.17% to Rs 359.25 at 11:53 IST. The stock was the biggest gainer in ...

The top Nifty gainers included Cipla which was jumped 4 percent while Grasim Industries gained 2.5 percent. Hero MotoCorp and Indiabulls Housing Finance along with Kotak Mahindra Bank were the other gainers.

The market breadth was in favour of the advances with 900 stocks advancing while 658 declined and 471 remained unchanged. On the other hand, in the BSE, 988 stocks advanced and 705 declined and 89 remained unchanged.

The report, however, did not mention the quantity of the product Last Updated at April 15, 2018 12:18 IST An employee works at the reception area of Cipla at its headquarters in Mumbai Pharma major Cipla's arm InvaGen Pharmaceuticals Inc is recalling 11 lots ...

Ankit Bhembre & Karthikeyan Thangarajan(Analysts, Ind-Ra) We expect Indian formulators to continue to make investments to grow their domestic non-prescription business through organic and inorganic routes. It would be driven by the need to further diversify ...

Mumbai : The key Indian equity markets traded marginally lower on Monday afternoon weighed on by heightened geo-political tensions in the Middle East, along with broadly negative cues from the Asian markets. Healthy buying in healthcare and fast moving ...

Cipla recovered from day#39;s low after the company clarified saying certain observations issued by the USFDA during product specific pre-approval inspection of Goa unit are procedural in nature.

Drug firm Cipla and Roche Pharma India has said that they have entered an agreement under which Cipla will promote and distribute tocilizumab and Syndyma, the 2nd brand of Roche's cancer therapy bevacizumab in India.This partnership is in line with Cipla and ...